A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine

This publication has 23 references indexed in Scilit:

• The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
  Pharmacogenetics, 1994
• Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
  1993
• Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype
  Pharmacogenetics, 1991
• THE HUMAN CYP2D LOCUS ASSOCIATED WITH A COMMON GENETIC-DEFECT IN DRUG OXIDATION - A G1934-]A BASE CHANGE IN INTRON-3 OF A MUTANT CYP2D6 ALLELE RESULTS IN AN ABERRANT-3' SPLICE RECOGNITION SITE
  1990
• Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
  European Journal of Clinical Pharmacology, 1990
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
  The Lancet, 1990
• Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
  Nature, 1988
• Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities
  Clinical Pharmacology & Therapeutics, 1982
• Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
  European Journal of Clinical Pharmacology, 1979
• Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins
  Journal of Molecular Biology, 1978